Wolfgang Miesbach: What Does Acquired Haemophilia A Truly cost, Clinically and Economically?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Real-world data from Munich – what does acquired haemophilia A truly cost, clinically and economically?
Great data presented at GTH2026 in Bonn by Seidl, Weiglein, Möhnle et al. from University Hospital LMU Munich – a retrospective single-center analysis of 51 adult AHA patients diagnosed between 2011 and 2023.
Patient characteristics:
- Median age 76 years – elderly, multimorbid
- Median FVIII activity 4% Median inhibitor titer 19 BU Median aPTT 72 sec
- Median hospital stay 38 days | Median ICU stay 10.5 days
- Etiology: 59% idiopathic, 27% autoimmune, 8% malignancy-associated, 6% postpartum
Clinical outcomes:
- 100-day mortality nearly 12%, 1-year mortality nearly 19%
- Early deaths primarily bleeding- and infection-related
- Severe bleeding (EACH2) independently associated with reduced overall survival (p is equal to 0.002)
- Low baseline FVIII activity independently predicted worse outcomes
Treatment reality:
43% steroids alone – but 57% needed combination immunosuppression
Emicizumab used for bleeding prophylaxis in 5 patients (9.8%)
The cost dimension for the period 2011-2023:
Median in-hospital drug costs: €130,069 per patient
More than 95% driven by bypassing agents and factor replacement”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention
-
Jul 6, 2026, 19:23Rob Mac Sweeney: Anticoagulation Strategies for Cardiopulmonary Bypass in Heparin-Induced Thrombocytopenia
-
Jul 6, 2026, 19:22Nthabiseng Bapela: Interpreting INR in Patients on Warfarin – A Practical Clinical Framework
-
Jul 6, 2026, 19:20Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
-
Jul 6, 2026, 18:58Mostafa Faisal: High PNH Type II Neutrophil Proportions Are Associated With Thrombosis
-
Jul 6, 2026, 17:57When Hematocrit Exceeds 70 Percent: Challenges in Peripheral Blood Smear Evaluation and CBC Analysis – Seema Dawood
-
Jul 6, 2026, 17:382026 ACC/AHA Multisociety Dyslipidemia Guideline: Key Updates for Vascular Specialists – Batool Abuhalimeh
-
Jul 6, 2026, 17:27Nicolas Gendron: Should Carbon Footprint Influence Therapeutic Decisions?
-
Jul 6, 2026, 17:15Sanchit Sharma։ Continuous Anticoagulation in PVT with Varices